Program
2019-nCoV Vaccine mRNA-1273
Also written as “mRNA-1273”, “mRNA-1273.815” and “mRNA-1273.529”.
Its studies are mostly in COVID-19 · Coronavirus Infections · Papillomavirus Infections · Influenza, Human, led by 4 companies.
Drug page2019-nCoV Vaccine mRNA-1273: every studyAll 41 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Modernaits history only | 173 open or running | phase 4since Sep 3, 2024 | May 13, 2020 | Dec 11, 2026phase 4 · NCT07863635 |
| Merckits history only | 10 open or running | phase 3since Nov 10, 2021 | Nov 10, 2021 | none ahead |
| Regeneron Pharmaceuticals | 10 open or running | phase 2since Apr 19, 2021 | Apr 19, 2021 | none ahead |
| Takedaits history only | 10 open or running | phase 2since Dec 18, 2020 | Dec 18, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 19, 2021First study: phase 2 study in HealthyFirst studyNCT04852978 · 295 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the full-length, prefusion stabilized spike (S) protein of SARS-CoV-2, ”NCIt, by rule
“Spike glycoprotein vaccine antigen”ChEMBL 37, by rule
Studies
The one study Regeneron Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04852978Healthy · United States | 2 | Completed | Nov 21, 2022 | 295 |
How it is read
Names in the registry
- “mRNA-1273”, 10 entries
- “mRNA-1273.815”, 3 entries
- “mRNA-1273.529”, 2 entries
- “mRNA-1273 Variant-containing Formulation”, 1 entry
- “mRNA-1273 Vaccine”, 1 entry
Codes read as this program: MRNA1273.
Conditions, from the studies’ own filings
- COVID-19, 15 studies
- Coronavirus Infections, 1 study
- Papillomavirus Infections, 1 study
- Influenza, Human, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.